Abstracts tagged "Outcome measures"

Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1032 • ACR Convergence 2024
Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities
Alexis Barbut¹, Marsha Jackson², Krista Kowiak², Julie McIntyre² and Allen Anandarajah¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Rheumatoid Arthritis (RA) is often associated with comorbidities including hypertension, cardiovascular disease, osteoporosis, lung disease, and eye involvement. Studies suggests that the average RA…
Abstract Number: 1341 • ACR Convergence 2024
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
Santiago Dans Caballero¹, Marta Rojas Giménez², Clementina López Medina³, Andrea Cid Chaves², Mónica Rico-Muñoz³, mitndbaim aelohim parra Moreno² and Alejandro Escudero-Contreras⁴, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 2087 • ACR Convergence 2024
Association of MRI-Defined Structure Features at Baseline with Knee Pain and Function Trajectories: Data from the Osteoarthritis Initiative (OAI)
Shen Liu¹, Thang Doung², Yong Ge³, Xiaoxiao Sun⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Jeffery Duryea⁸ and Kent Kwoh⁹, and Osteoarthritis Initiative (OAI) and Pivotal Osteoarthritis MRI Analyses (POMA) investigators, ¹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹University of Arizona, Tucson, AZ
Background/Purpose: Characterizing knee symptom (i.e., pain and function) trajectories and understanding differences among symptom trajectories have the potential to promote the development of customized treatment…
Abstract Number: 2329 • ACR Convergence 2024
Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
Gretchen Ball¹, Hassan Hamade², Sarah Romanelli², Melissa Zundell², Sangyoon Shin², Thami Senthilkumaran², Angela Lamb², Saakshi Khattri³, Lourdes Perez Chada⁴, Joseph Merola⁵ and Alice Gottlieb⁶, ¹Albert Einstein College of Medicine, Ridgefield, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Mount Sinai Medical Center, New York, NY, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Newton, MA, ⁶Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is frequently undiagnosed and/or undertreated. Given the elevated risk of disability with treatment delays, we launched a quality improvement initiative to…
Abstract Number: 0136 • ACR Convergence 2024
Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
Federico Zazzetti¹, Urbano Sbarigia², William Giovanini³, Claire Blacketer⁴, Michel van Speybroeck⁵, Teresa A. Simon⁶, Guo Li³, Chetan S. Karyekar⁴, Reyhan Sonmez⁷, Manuel Ugarte-Gil⁸, RV, Gamboa-Cardenas⁹, Victor Pimentel-Quiroz¹⁰, Guillermo Pons-Estel¹¹, Bernardo Pons-Estel¹², Rosana Quintana¹³, Veronica Saurit¹⁴, ODIRLEI MONTICIELO¹⁵, Katiuzka Zuñiga Corrales¹⁶, Jorge Esquivel-Valerio¹⁷, Martin Rebella¹⁸, Cecilia Pisoni¹⁹, Francinne Machado Ribeiro²⁰, Carlos Núñez-Álvarez²¹, Kaleb Michaud²², Patricia Katz²³, Rangi Kandane-Rathnayake²⁴, Eric Morand²⁵, Worawit Louthrenoo²⁶, Yi-Hsing Chen²⁷, Jiacai Cho²⁸, Laniyati Hamijoyo²⁹, Shue Fen Luo³⁰, Yeong-Jian Jan Wu³⁰, Sandra Navarra³¹, Sargunan Sockalingam³², Masayoshi Harigai³³, Zhuoli Zhang³⁴, BMDB Basnayake³⁵, Madelynn Chan³⁶, Tsutomu Takeuchi³⁷, Sang-Cheol Bae³⁸, Fiona Goldblatt³⁹, Sean O'Neill⁴⁰, Kristine (Pek Ling) Ng⁴¹, Yih Jia Poh⁴², Nicola Tugnet⁴³, Sunil Kumar⁴⁴, Michael Tee⁴⁵, Yoshiya Tanaka⁴⁶ and Chak Sing. Lau⁴⁷, Alberta Hoi⁴⁸, Mandana Nikpour⁴⁹, Mark Sapsford⁵⁰, Íñigo Rúa-Figueroa⁵⁰, José María Pego-Reigosa⁵¹, María Galindo-Izquierdo⁵², Jaime Calvo-Alén⁵³, Antonio Fernández-Nebro⁵⁴, Raúl Menor Almagro⁵⁵ and Frederic Lavie⁵⁶, ¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Physicians Research Center, LLC, Toms River, NJ, ⁷EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ⁹Universidad Científica del Sur, Lima, Lima, Peru, ¹⁰Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ¹³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁴hospital privado universitario de cordoba, Córdoba, Argentina, ¹⁵HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁶Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ¹⁷Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ¹⁸Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ¹⁹CEMIC, Buenos Aires, Argentina, ²⁰Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²²University of Nebraska Medical Center, Omaha, NE, ²³University of California San Francisco, San Francisco, CA, ²⁴Monash University, Clayton, Victoria, Australia, ²⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²⁶Chiang Mai University, Chang Wat Chiang Mai, Thailand, ²⁷Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ²⁸National University Hospital, Kent Ridge, Singapore, ²⁹University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, ³⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), ³¹University of Santo Tomas, Manila, Philippines, ³²University of Malaya Medical Centre, Kuala Lumpur, Malaysia, ³³Tokyo Women's Medical University, Tokyo, Japan, ³⁴Peking University First Hospital, Beijing, China, ³⁵Teaching Hospital, Kandy, Sri Lanka, ³⁶Tan Tock Seng Hospital, Singapore, Singapore, ³⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³⁹Flinders Medical Centre, Adelaide, Australia, ⁴⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ⁴¹Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, ⁴²SingHealth, Singapore, Singapore, ⁴³Auckland District Health Board, Auckland, New Zealand, ⁴⁴Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, ⁴⁵University of the Philippines, Manila, Philippines, ⁴⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴⁷University of Hong Kong, Pok Fu Lam, Hong Kong, ⁴⁸Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ⁴⁹The University of Sydney, Melbourne, Victoria, Australia, ⁵⁰Middlemore Hospital, Auckland, New Zealand, ⁵⁰Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁶Galicia Health Service (SERGAS), Vigo, Spain, ⁵²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵³Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁵⁴Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ⁵⁵Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁵⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
Abstract Number: 0364 • ACR Convergence 2024
Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends
Insa Mannstadt¹, J. Alex B. Gibbons² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 0721 • ACR Convergence 2024
Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study
Xavier Puéchal¹, Michele Iudici¹, Elodie Perrodeau², Claire Goulvestre³, Pascal cohen⁴, Alexis Régent¹, Luc Mouthon⁵, Loïc Guillevin⁴, Raphael Porcher⁶ and Benjamin Terrier⁷, ¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²Hôtel-Dieu, Paris, France, ³Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a frequently relapsing disease for which a meta-analysis concluded that an increase or persistence of ANCA during remission is only…
Abstract Number: 1036 • ACR Convergence 2024
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
Rosemary Gedert¹, Danielle Ochocki¹, Neda Kortam¹, Suiyuan Huang¹, Vivek Nagaraja², Katherine Chakrabarti¹, Julia Ford¹, Martin Garber¹, Jiha Lee¹, Vladimir Ognenovski¹, David Roofeh³, David Cella⁴ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Rutgers-RWJ Medical School, New Brunswick, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient.…
Abstract Number: 1344 • ACR Convergence 2024
Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
Rathnam Venkat¹, Keigo Hayashi², Pierre-Antoine Juge³, Gregory McDermott², Misti Paudel⁴, Xiaosong Wang⁵, Kathleen Vanni⁵, Emily Kowalski⁶, Grace Qian⁵, Katarina Bade⁶, Alene Saavedra⁶, Kevin Mueller⁶, Sung Hae Chang⁷, Paul Dellaripa⁶, Michael Weinblatt⁸, Nancy Shadick⁵, Tracy J Doyle⁹, Philippe Dieudé¹⁰ and Jeffrey Sparks¹¹, ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women’s Hospital, Brookline, MA, ³Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham and Women's Hospital, West Roxbury, MA, ¹⁰Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous with about half of patients having progressive disease. However, the rates of progression and the association…
Abstract Number: 1591 • ACR Convergence 2024
Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
Valerio maniscalco¹, Simone Appenzeller², Jennifer lemon³, Lucy stead⁴, Natalia Vasquez Canizares⁵, Gabriele Simonini⁶, Suzanne Li⁷ and Clare Pain⁸, and IJOG study, ¹Santo Stefano Hospital; Meyer Children Hospital IRCCS, Firenze, Toscana, Italy, ²Unicamp, Campinas, SP, Brazil, ³Alder Hey Children's NHS Foundation Trust, Liverpool, ⁴Liverpool University, Liverpool, ⁵Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, ⁶Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ⁷Hackensack University Medical Center, Hackensack, ⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease that primary affect the vascular system determining multiple organ damage and reducing quality of life…
Abstract Number: 2137 • ACR Convergence 2024
Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center
Annmarie Miranda¹, Adil Vural², Chao Zhang³, Jennifer Varley⁴, Walaa Abu Alya⁵, Komal Mushtaq⁶, Marie Budev¹, Abby Abelson¹, Chad Deal⁷ and Sarah Keller¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Avon, OH, ³Cleveland Clinic, Cleveland Heights, OH, ⁴Heritage College of Osteopathic Medicine, Ohio University, Beachwood, OH, ⁵An-najah National University., Westlake, OH, ⁶Cleveland Clinic, Fairview Park, OH, ⁷Cleveland Clinic, Shaker Heights, OH
Background/Purpose: The incidence of fractures due to osteoporosis (OP) is increased in patients with end-stage lung disease and fractures are a well-known complication of lung…

« Previous Page
1
…
4
5
6
7
8
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].